What does procollagen C-endopeptidase enhancer protein 2 have to do with HDL-cholesteryl ester uptake? Or how I learned to stop worrying and love reverse cholesterol transport?

Current Opinion in Lipidology

Volumn 26, Issue 5, 2015, Pages 420-425

  Sorci Thomas, Mary G ^a   Pollard, Ricquita D ^b   Thomas, Michael J ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cholesteryl esters; Extracellular matrix; HDL; Procollagen c endopeptidase enhancer 2; Scavenger receptor class b1

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL ESTER; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PROCOLLAGEN C ENDOPEPTIDASE ENHANCER PROTEIN 2; PROTEIN; SCAVENGER RECEPTOR BI; UNCLASSIFIED DRUG; GLYCOPROTEIN; HDL CHOLESTERYL ESTER; PCOLCE2 PROTEIN, HUMAN; SCLEROPROTEIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CATABOLISM; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; ANIMAL; METABOLISM; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL TRANSPORT; CHOLESTEROL ESTERS; EXTRACELLULAR MATRIX PROTEINS; GLYCOPROTEINS; HUMANS; LIPOPROTEINS, HDL;

EID: 84944345774     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000211     Document Type: Review

References (76)

1. Castelli WP, Doyle JT, Gordon T, et al. HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study. Circulation 1977; 55:767-772.
2. Sorci-Thomas MG, Thomas MJ. Why targeting HDL should work as a therapeutic tool, but has not. J Cardiovasc Pharmacol 2013; 62:239- 246.
3. de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, et al. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol 2010; 30:796-801.
4. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011; 364:127-135.
5. Rohatgi A, Khera A, Berry JD, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 2014; 371:2383-2393.
6. Mulya A, Lee JY, Gebre AK, et al.Minimal lipidation of prebeta HDL by ABCA1 results in reduced ability to interact with ABCA1. Arterioscler Thromb Vasc Biol 2007; 27:1828-1836.
7. Mulya A, Lee JY, Gebre AK, et al. Initial interaction of apoA-I with ABCA1 impacts in vivo metabolic fate of nascent HDL. J Lipid Res 2008; 49:2390- 2401.
8. Du X, Kim MJ, Hou L, et al. HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export. Circ Res 2015; 116:1133-1142.
9. Favari E, Lee M, Calabresi L, et al. Depletion of prebeta-high density lipoprotein by human chymase impairs ATP-binding cassette transporter A1- but not scavenger receptor class B type I-mediated lipid efflux to high density lipoprotein. J Biol Chem 2004; 279:9930-9936.
10. Asztalos BF, de la Llera-Moya M, Dallal GE, et al. Differential effects of HDL subpopulations on cellular ABCA1-And SR-BI-mediated cholesterol efflux. J Lipid Res 2005; 46:2246-2253.
11. Phillips MC. Molecular mechanisms of cellular cholesterol efflux. J Biol Chem 2014; 289:24020-24029.
12. Tuteja S, Rader DJ. High-density lipoproteins in the prevention of cardiovascular disease: changing the paradigm. Clin Pharmacol Ther 2014; 96:48-56.
13. Rosenson RS, Brewer HB Jr, Davidson WS, et al. Cholesterol efflux and atheroprotection: Advancing the concept of reverse cholesterol transport. Circulation 2012; 125:1905-1919.
14. Getz GS, Reardon CA. Cubbing in proapolipoprotein maturation. J Lipid Res 2011; 52:1861-1864.
15. Fielding CJ, Fielding PE. Caveolae and intracellular trafficking of cholesterol. Adv Drug Deliv Rev 2001; 49:251-264.
16. Denis M, Landry YD, Zha X. ATP-binding cassette A1-mediated lipidation of apolipoprotein A-I occurs at the plasma membrane and not in the endocytic compartments. J Biol Chem 2008; 283:16178-16186.
17. Chau P, Fielding PE, Fielding CJ. Bone morphogenetic protein-1 (BMP-1) cleaves human proapolipoprotein A1 and regulates its activation for lipid binding. Biochemistry 2007; 46:8445-8450.
18. Chau P, Nakamura Y, Fielding CJ, Fielding PE. Mechanism of prebeta-HDL formation and activation. Biochemistry 2006; 45:3981-3987.
19. Sviridov D. Maturation of apolipoprotein A-I: unrecognized health benefit or a forgotten rudiment? J Lipid Res 2009; 50:1257-1258.
20. Sorci-Thomas MG, Owen JS, Fulp B, et al. Nascent high density lipoproteins formed by ABCA1 resemble lipid rafts and are structurally organized by three ApoA-I monomers. J Lipid Res 2012; 53:1890-1909.
21. Gordon JI, Smith DP, Andy R, et al. The primary translation product of rat intestinal apolipoprotein A-I mRNA is an unusual preproprotein. J Biol Chem 1982; 257:971-978.
22. Brewer HB Jr, Fairwell T, Kay L, et al. Human plasma proapoA-I: isolation and amino-Terminal sequence. Biochem Biophys Res Commun 1983; 113:626- 632.
23. Zannis VI, Karathanasis SK, Keutmann HT, et al. Intracellular and extracellular processing of human apolipoprotein A-I: secreted apolipoprotein A-I isoprotein 2 is a propeptide. Proc Natl Acad Sci U S A 1983; 80:2574-2578.
24. McLeod RS, Robbins C, Burns A, et al. Deletion of the propeptide of apolipoprotein A-I impairs exit of nascent apolipoprotein A-I from the endoplasmic reticulum. Biochem J 1994; 302:641-648.
25. Sviridov D, Fidge N. Efflux of intracellular versus plasma membrane cholesterol in HepG2 cells: different availability and regulation by apolipoprotein A-I. J Lipid Res 1995; 36:1887-1896.
26. Sviridov D, Pyle L, Fidge N. Identification of a sequence of apolipoprotein A-I associated with the efflux of intracellular cholesterol to human serum and apolipoprotein A-I containing particles. Biochemistry 1996; 35:189-196.
27. Sviridov D, Pyle LE, Jauhiainen M, et al. Deletion of the propeptide of apolipoprotein A-I reduces protein expression but stimulates effective conversion of prebeta-high density lipoprotein to alpha-high density lipoprotein. J Lipid Res 2000; 41:1872-1882.
28. Pyle LE, Sviridov D, Fidge NH. Characterization of the maturation of human pro-Apolipoprotein A-I in an in vitro model. Biochemistry 2001; 40:3101- 3108.
29. Sviridov D, Fidge N, Beaumier-Gallon G, Fielding C. Apolipoprotein A-I stimulates the transport of intracellular cholesterol to cell-surface cholesterol- rich domains (caveolae). Biochem J 2001; 358:79-86.
30. Asharani PV, Keupp K, Semler O, et al. Attenuated BMP1 function compromises osteogenesis, leading to bone fragility in humans and zebrafish. Am J Hum Genet 2012; 90:661-674.
31. Hartigan N, Garrigue-Antar L, Kadler KE. Bone morphogenetic protein-1 (BMP-1). Identification of the minimal domain structure for procollagen C-proteinase activity. J Biol Chem 2003; 278:18045-18049.
32. Ricard-Blum S, Bernocco S, Font B, et al. Interaction properties of the procollagen C-proteinase enhancer protein shed light on the mechanism of stimulation of BMP-1. J Biol Chem 2002; 277:33864-33869.
33. Bekhouche M, Kronenberg D, Vadon-Le Goff S, et al. Role of the netrin-like domain of procollagen C-proteinase enhancer-1 in the control of metalloproteinase activity. J Biol Chem 2010; 285:15950-15959.
34. Goldsmith EC, Bradshaw AD, Spinale FG. Cellular mechanisms of tissue fibrosis. 2. Contributory pathways leading to myocardial fibrosis: moving beyond collagen expression. Am J Physiol Cell Physiol 2013; 304:C393- C402.
35. Steiglitz BM, Greenspan DS. Assignment of the mouse Pcolce2 gene, which encodes procollagen C-proteinase enhancer protein 2, to chromosome 9 and localization of PCOLCE2 to human chromosome 3q23. Cytogenet Cell Genet 2001; 95:244-245.
36. Steiglitz BM, Keene DR, Greenspan DS. PCOLCE2 encodes a functional procollagen C-proteinase enhancer (PCPE2) that is a collagen-binding protein differing in distribution of expression and posttranslational modification from the previously described PCPE1. J Biol Chem 2002; 277:49820- 49830.
37. Kronenberg D, Vadon-Le Goff S, Bourhis JM, et al. Strong cooperativity and loose geometry between CUB domains are the basis for procollagen cproteinase enhancer activity. J Biol Chem 2009; 284:33437-33446.
38. Blanc G, Font B, Eichenberger D, et al. Insights into how CUB domains can exert specific functions while sharing a common fold: conserved and specific features of the CUB1 domain contribute to the molecular basis of procollagen C-proteinase enhancer-1 activity. J Biol Chem 2007; 282:16924-16933.
39. Bourhis JM, Vadon-Le Goff S, Afrache H, et al. Procollagen C-proteinase enhancer grasps the stalk of the C-propeptide trimer to boost collagen precursor maturation. Proc Natl Acad Sci U S A 2013; 110:6394-6399.
40. Bernocco S, Steiglitz BM, Svergun DI, et al. Low resolution structure determination shows procollagen C-proteinase enhancer to be an elongated multidomain glycoprotein. J Biol Chem 2003; 278:7199-7205.
41. Vadon-Le Goff S, Kronenberg D, Bourhis JM, et al. Procollagen C-proteinase enhancer stimulates procollagen processing by binding to the C-propeptide region only. J Biol Chem 2011; 286:38932-38938.
42. Daly NL, Djordjevic JT, Kroon PA, Smith R. Three-dimensional structure of the second cysteine-rich repeat from the human low-density lipoprotein receptor. Biochemistry 1995; 34:14474-14481.
43. Daly NL, Scanlon MJ, Djordjevic JT, et al. Three-dimensional structure of a cysteine-rich repeat from the low-density lipoprotein receptor. Proc Natl Acad Sci U S A 1995; 92:6334-6338.
44. Liepinsh E, Banyai L, Pintacuda G, et al. NMR structure of the netrin-like domain (NTR) of human type I procollagen C-proteinase enhancer defines structural consensus of NTR domains and assesses potential proteinase inhibitory activity and ligand binding. J Biol Chem 2003; 278:25982-25989.
45. Banyai L, Patthy L. The NTR module: domains of netrins, secreted frizzled related proteins, and type I procollagen C-proteinase enhancer protein are homologous with tissue inhibitors of metalloproteases. Protein Sci 1999; 8:1636-1642.
46. Ulmasov B, Oshima K, Rodriguez MG, et al. Differences in the degree of cerulein-induced chronic pancreatitis in C57BL/6 mouse substrains lead to new insights in identification of potential risk factors in the development of chronic pancreatitis. Am J Pathol 2013; 183:692-708.
47. Hosper NA, Bank RA, van den Berg PP. Human amniotic fluid-derived mesenchymal cells from fetuses with a neural tube defect do not deposit collagen type i protein after TGF-beta1 stimulation in vitro. Stem Cells Dev 2014; 23:555-562.
48. Tintle NL, Pottala JV, Lacey S, et al. A genome-wide association study of saturated, mono-And polyunsaturated red blood cell fatty acids in the Framingham Heart Offspring Study. Prostaglandins Leukot Essent Fatty Acids 2015; 94:65-72.
49. Baicu CF, Zhang Y, Van Laer AO, et al. Effects of the absence of procollagen C-endopeptidase enhancer-2 on myocardial collagen accumulation in chronic pressure overload. Am J Physiol Heart Circ Physiol 2012; 303:H234- H240.
50. Zhu J, Gardner J, Pullinger CR, et al. Regulation of apoAI processing by procollagen C-proteinase enhancer-2 and bone morphogenetic protein-1. J Lipid Res 2009; 50:1330-1339.
51. Hinds DA, Seymour AB, Durham LK, et al. Application of pooled genotyping to scan candidate regions for association with HDL cholesterol levels. Hum Genomics 2004; 1:421-434.
52. Xu H, Acott TS, Wirtz MK. Identification and expression of a novel type I procollagen C-proteinase enhancer protein gene from the glaucoma candidate region on 3q21-q24. Genomics 2000; 66:264-273.
53. Francone OL, Ishida BY, de la Llera-Moya M, et al. Disruption of the murine procollagen C-proteinase enhancer 2 gene causes accumulation of proapoA- I and increased HDL levels. J Lipid Res 2011; 52:1974-1983.
54. Heinzel K, Bleul CC. The Foxn1-dependent transcripts PCOLCE2 and mPPP1R16B are not required for normal thymopoiesis. Eur J Immunol 2007; 37:2562-2571.
55. Miles RR, Perry W, Haas JV, et al. Genome-wide screen for modulation of hepatic apolipoprotein A-I (ApoA-I) secretion. J Biol Chem 2013; 288:6386- 6396.
56. Pollard jD, Blesso CN, Zabalawi M, et al. Procollagen C-endopeptidase enhancer protein 2 (PCPE2) reduces atherosclerosis in mice by enhancing SR-BI mediated HDL-cholesteryl ester uptake. J Biol Chem 2015; 290:15496-15511.
57. Rigotti A, Trigatti B, Babitt J, et al. Scavenger receptor BI -A cell surface receptor for high density lipoprotein. Curr Opin Lipidol 1997; 8:181-188.
58. Rigotti A, Trigatti BL, Penman M, et al. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc Natl Acad Sci U S A 1997; 94:12610-12615.
59. Zhang Y, Da Silva JR, Reilly M, et al. Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. J Clin Invest 2005; 115:2870-2874.
60. West M, Greason E, Kolmakova A, et al. Scavenger receptor class B type I protein as an independent predictor of high-density lipoprotein cholesterol levels in subjects with hyperalphalipoproteinemia. J Clin Endocrinol Metab 2009; 94:1451-1457.
61. Vickers KC, Rodriguez A. Human scavenger receptor class B type I variants, lipid traits, and cardiovascular disease. Circ Cardiovasc Genet 2014; 7:735- 737.
62. Niemsiri V, Wang X, Pirim D, et al. Impact of genetic variants in human scavenger receptor class B type I (SCARB1) on plasma lipid traits. Circ Cardiovasc Genet 2014; 7:838-847.
63. Vergeer M, Korporaal SJ, Franssen R, et al. Genetic variant of the scavenger receptor BI in humans. N Engl J Med 2011; 364:136-145.
64. Neculai D, Schwake M, Ravichandran M, et al. Structure of LIMP-2 provides functional insights with implications for SR-BI and CD36. Nature 2013; 504:172-176.
65. Chadwick AC, Jensen DR, Peterson FC, et al. Expression, purification and reconstitution of the C-Terminal transmembrane domain of scavenger receptor BI into detergent micelles for NMR analysis. Protein Expr Purif 2015; 107:35-42.
66. Babitt J, Trigatti B, Rigotti A, et al. Murine SR-BI, a high density lipoprotein receptor that mediates selective lipid uptake, is N-glycosylated and fatty acylated and colocalizes with plasma membrane caveolae. J Biol Chem 1997; 272:13242-13249.
67. Meyer JM, Graf GA, van der Westhuyzen DR. New developments in selective cholesteryl ester uptake. Curr Opin Lipidol 2013; 24:386-392.
68. Rohrl C, Eigner K, Winter K, et al. Endoplasmic reticulum stress impairs cholesterol efflux and synthesis in hepatic cells. J Lipid Res 2014; 55:94- 103.
69. Sahoo D, Peng Y, Smith JR, et al. Scavenger receptor class B, type I (SR-BI) homo-dimerizes via its C-Terminal region: fluorescence resonance energy transfer analysis. Biochim Biophys Acta 2007; 1771:818-829.
70. Gaidukov L, Nager AR, Xu S, et al. Glycine dimerization motif in the N-Terminal transmembrane domain of the high density lipoprotein receptor SR-BI required for normal receptor oligomerization and lipid transport. J Biol Chem 2011; 286:18452-18464.
71. Kocher O, Yesilaltay A, Cirovic C, et al. Targeted disruption of the PDZK1 gene in mice causes tissue-specific depletion of the high density lipoprotein receptor scavenger receptor class B type I and altered lipoprotein metabolism. J Biol Chem 2003; 278:52820-52825.
72. Canton J, Neculai D, Grinstein S. Scavenger receptors in homeostasis and immunity. Nat Rev Immunol 2013; 13:621-634.
73. Mineo C, Shaul PW. Regulation of signal transduction by HDL. J Lipid Res 2013; 54:2315-2324.
74. Gao M, Zhao D, Schouteden S, et al. Regulation of high-density lipoprotein on hematopoietic stem/progenitor cells in atherosclerosis requires scavenger receptor type BI expression. Arterioscler Thromb Vasc Biol 2014; 34:1900- 1909.
75. Feng H, Guo L, Wang D, et al. Deficiency of scavenger receptor BI leads to impaired lymphocyte homeostasis and autoimmune disorders in mice. Arterioscler Thromb Vasc Biol 2011; 31:2543-2551.
76. Curtiss LK, Valenta DT, Hime NJ, Rye KA. What is so special about apolipoprotein AI in reverse cholesterol transport? Arterioscler Thromb Vasc Biol 2006; 26:12-19.